Protein Kinase C Activity in Human Leukemia Cell Lines with Reference to Sensitivity to Antineoplastic Agents.

Shunichi Sugawara(Sendai Kousei Hospital), Masakichi Motomiya(Tohoku University), Nobuko Kumano(Tohoku University), Yasuo Saijo(Ho Chi Minh City International University), Yuka Numata(Chugoku Rosai Hospital), Shuji Suzuki(Tokyo Institute of Technology), George Sato(Tohoku University)
The Tohoku Journal of Experimental Medicine
January 1, 1992
10.1620/tjem.168.393
Cited by 3

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642